Display options
Cite
Currie DC, Lueck C, Milburn HJ, et al. Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis. Thorax. 1990;45(6):447-50doi: 10.1136/thx.45.6.447.
Currie, D. C., Lueck, C., Milburn, H. J., Harvey, C., Longbottom, J. L., Darbyshire, J. H., Nunn, A. J., & Cole, P. J. (1990). Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis. Thorax, 45(6), 447-50. https://doi.org/10.1136/thx.45.6.447
Currie, D C, et al. "Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis." Thorax vol. 45,6 (1990): 447-50. doi: https://doi.org/10.1136/thx.45.6.447
Currie DC, Lueck C, Milburn HJ, Harvey C, Longbottom JL, Darbyshire JH, Nunn AJ, Cole PJ. Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis. Thorax. 1990 Jun;45(6):447-50. doi: 10.1136/thx.45.6.447. PMID: 2203181; PMCID: PMC462527.
Copy Download .nbib Format: NLM
Share it on
Full text links
HighWire Free PMC Article

Thorax. 1990 Jun;45(6):447-50. doi: 10.1136/thx.45.6.447.

Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis.

Thorax

D C Currie, C Lueck, H J Milburn, C Harvey, J L Longbottom, J H Darbyshire, A J Nunn, P J Cole

Affiliations

  1. Department of Thoracic Medicine, National Heart and Lung Institute, Brompton Hospital, London.

PMID: 2203181 PMCID: PMC462527 DOI: 10.1136/thx.45.6.447
Free PMC Article

Abstract

Allergic bronchopulmonary aspergillosis often requires treatment with oral corticosteroids to control the host response to Aspergillus fumigatus. In a double blind study 25 patients with allergic bronchopulmonary aspergillosis taking maintenance oral corticosteroids were randomly allocated to receive 5 mg natamycin or placebo by nebuliser twice daily for one year. The primary aim of the study was to assess the steroid sparing potential of natamycin. Standardised reductions in corticosteroid dosage were therefore undertaken every five weeks, unless clinically contraindicated. Five patients were withdrawn in the first four months: two (1 natamycin, 1 placebo) died, two (1 natamycin, 1 placebo) had suspected drug reactions, and one (natamycin) was non-compliant. The pretreatment characteristics of the 20 patients (10 in each group) who completed the study were similar, 17 (9 natamycin, 8 placebo) having evidence of recent disease activity. At the end of the study prednisolone dose had been reduced by a similar amount in each group (median natamycin 2.25 mg, placebo 2.5 mg). Evidence of disease activity during the study year (transient shadowing on the chest radiograph, blood eosinophilia, or increases in antibodies to A fumigatus, or any combination of these) was observed in similar numbers of patients in each group (5 natamycin, 7 placebo). There was no evidence that natamycin conferred benefit on these patients with allergic bronchopulmonary aspergillosis.

Similar articles

Show all 8 similar articles

Cited by

References

  1. Clin Allergy. 1976 May;6(3):209-17 - PubMed
  2. J Pediatr. 1977 Dec;91(6):914-7 - PubMed
  3. J Allergy Clin Immunol. 1978 Aug;62(2):91-5 - PubMed
  4. Br Med J (Clin Res Ed). 1987 Feb 14;294(6569):419-22 - PubMed
  5. Thorax. 1987 Jan;42(1):26-31 - PubMed
  6. Thorax. 1968 Nov;23(6):571-81 - PubMed
  7. Am Rev Respir Dis. 1959 Aug;80:167-80 - PubMed
  8. Br Med J. 1968 Mar 16;1(5593):661-5 - PubMed
  9. Lancet. 1968 May 18;1(7551):1089-90 - PubMed
  10. Thorax. 1968 Sep;23(5):519-23 - PubMed
  11. Lancet. 1964 Jun 20;1(7347):1349-53 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources